Q1 2026 Results Signal a Sector in Structural Transition

The first quarter of 2026 has offered a revealing and at times sobering update on the state of the global beauty industry.

Taken together, the thirteen companies tracked by CARRARA Advisory posted aggregate reported revenue growth of 2.6% -- a meaningful step up from the 1.7% recorded in the second half of 2025 and a clear reversal from the near-flat performance of H1 last year. At nearly $125 billion in combined yearly revenues, this group serves as CARRARA's primary tool for sense-checking the health of the global beauty industry.

There is no single authoritative real-time indicator for global beauty performance: market data providers publish with a lag, and no solid and reliable index captures the full breadth of the sector. What a carefully curated portfolio of publicly reporting companies can provide, however, is a timely and multi-dimensional read on where the industry actually stands.

This quarter CARRARA has expanded its coverage to thirteen companies, adding Galderma, PROYA and Kenvue alongside the existing ten, with the explicit goal of broadening the lens across categories, price tiers and geographies. The universe now spans injectable aesthetics and therapeutic dermatology at one end, mass cosmetics, fragrances and personal care at the other, and everything in between; it includes companies with primary exposure to China, Korea, Europe and the United States; and it ranges from ultra-premium luxury to accessible value. The divergences across these thirteen companies are now sharper than they have been at any point in the past three years -- and it is precisely that breadth of coverage that makes those divergences analytically meaningful.

The headline number, however, masks a story that is far more nuanced. The beauty market at large is not recovering uniformly. What is emerging instead is a bifurcated landscape defined by two accelerating poles: clinical and science-backed efficacy at one end, and accessible value at the other. The comfortable middle ground that once sustained many of the industry's largest and most storied franchises is shrinking.

A Sector Confronting Its Own Slowdown

Before turning to individual company results, the trend line deserves careful attention -- because it tells a story that the industry has rarely had to confront.

For more than two decades, global beauty has been one of the most reliably growing consumer sectors in the world, expanding at a compound rate of roughly 4 to 5% annually through economic cycles, technological disruption, and shifting consumer preferences. The only meaningful interruptions to this trajectory were the 2008-2009 financial crisis, when discretionary spending contracted sharply, and the COVID-19 pandemic in 2020, when physical retail shutdowns temporarily paralyzed large segments of the market. In both cases, the industry recovered quickly and resumed its long-run pace.

What happened in 2025 was different, and more unsettling, precisely because it did not have a single visible cause. The thirteen companies in the CARRARA universe closed calendar year 2025 with aggregate revenue growth of just 0.6% -- one of the weakest performances this group has collectively delivered outside of an acute external shock. The year was internally divided: H1 2025 was essentially flat at negative 0.4%, and H2 recovered modestly to 1.7%, suggesting some stabilization in the second half. But the full-year result was still dramatically below the industry's historical norm.

Q1 2026, at 2.6%, continues the directional improvement. The trajectory -- from negative 0.4% in H1 2025, to 1.7% in H2 2025, to 2.6% in Q1 2026 -- is encouraging, and it would be wrong to dismiss it. But it is equally wrong to declare a return to normalcy. Even at 2.6%, this universe is still growing at roughly half the pace the industry has sustained for most of the past two decades. The question that now preoccupies both management teams and investors is whether this is a cyclical trough nearing its end, or whether the industry has structurally downshifted to a lower long-run growth rate.

The evidence, at this stage, supports neither conclusion definitively. What it does show is that the recovery, where it is happening, is narrow: concentrated in companies and categories with strong clinical or value credentials, while the broad middle of the market continues to struggle. A true return to 4 to 5% aggregate growth would require companies that are currently restructuring -- Estee Lauder, Coty, Unilever, Shiseido -- to return to meaningful organic expansion, and for the China market to fully normalize. Neither appears imminent.

The Standouts: Galderma, e.l.f. Beauty, and Kenvue Lead the Pack

The three fastest-growing companies in the CARRARA universe this quarter share a common thread: each occupies a clearly defined and defensible position that happens to align with where consumer demand is gravitating.

Galderma delivered the most striking result in our coverage, posting 30.5% reported revenue growth and reaching $1.47 billion in net sales for the quarter. At constant currency, growth was 25.5%, broad-based across all three of its segments. Unlike e.l.f.'s acquisition-inflated number, Galderma's growth seems to be entirely organic -- the company has made no significant acquisitions, and its expansion reflects the commercial ramp-up of internally developed products and a disciplined integrated dermatology strategy.

The standout driver seems to be Nemluvio (nemolizumab), Galderma's own biologic drug for prurigo nodularis and atopic dermatitis, which received FDA approval in August 2024 and has since been rolling out internationally. Nemluvio generated $452 million in full-year 2025 net sales and continued to accelerate in Q1 2026, driving a 71.3% surge in therapeutic dermatology to $385 million for the quarter ($185M by Nemluvio vs $39M in Q1 2025). This is a product Galderma developed internally, not acquired -- making it a genuine organic innovation story. The company has now doubled its peak sales projection for Nemluvio to over $4 billion, and expects the drug to reach financial breakeven in 2026, a year ahead of initial expectations. Injectable aesthetics grew 13.1%, with neuromodulators reaching $364 million and fillers and biostimulators $284 million. Dermatological skincare advanced 17%, driven by Cetaphil and Alastin. Galderma's Q1 results prompted a 5% jump in its share price, and the trajectory reflects two macro forces simultaneously: the growing medicalization of skincare, as consumers and practitioners increasingly blur the line between dermatology and aesthetics, and the strong pharmaceutical pipeline dynamics of its prescription portfolio. Its ability to serve both the aesthetics consumer and the therapeutic patient through a single integrated dermatology platform is a competitive structure few rivals can replicate.

e.l.f. Beauty posted 35.1% revenue growth to reach $449 million in Q1, beating Wall Street estimates and sending the stock higher. However, the headline number requires important context: the vast majority of this growth is attributable to the acquisition of rhode, the skincare brand founded by Hailey Bieber, which e.l.f. acquired in August 2025 for $1 billion. Since rhode was not part of the company a year earlier, its revenues flow entirely into reported growth with no prior-year comparable. Company management has been explicit on this: in guidance provided for fiscal 2027, e.l.f. disclosed that rhode is expected to contribute approximately 9 percentage points to full-year net sales growth, and that organic growth for the core e.l.f. brand is forecast at only 4 to 5% annually. For Q1 CY2026 specifically, the organic e.l.f. brand was likely slightly negative, as management flagged it would be "down high single digits" in organic terms due to a demanding prior-year comparison caused by a shipping pull-forward ahead of an ERP system cutover. In other words, the reported 35.1% growth is essentially a rhode story: without the acquisition, e.l.f.'s core business was contracting modestly in this particular quarter.

None of this diminishes e.l.f.'s strategic achievement. The rhode acquisition -- completed at $1 billion for a brand that generated $212 million in net sales in its trailing year prior to the deal -- was an aggressive and well-timed bet on a brand with exceptional cultural momentum and a clear whitespace opportunity in the prestige-accessible skincare tier. Rhode's launch across Sephora North America and the UK has performed ahead of expectations, and the earnout structure tied to future performance suggests even the sellers believe the runway is long. The acquisition has transformed e.l.f. from a single-brand cosmetics company into a multi-brand portfolio operator. But for the purposes of assessing organic beauty market performance, the underlying e.l.f. core brand in Q1 2026 was essentially flat to slightly negative -- a very different story than the headline implies.

Kenvue delivered 8.4% growth in its skin health and beauty division, the company's strongest segment, while total net sales rose 4.5% to $3.9 billion. The Neutrogena brand benefited from sun care expansion in EMEA and a robust sun season in Latin America, while OGX drove hair care performance through its new Pro Growth collection. Kenvue's Q1 results also reflect successful supply chain optimization and productivity gains. The company is navigating its own strategic inflection, with the planned Kimberly-Clark acquisition -- a $48.7 billion deal announced in November 2025 -- expected to close in the second half of 2026 pending regulatory approvals. Kenvue is a compelling case study in the value of anchoring a beauty and personal care portfolio in dermatologically validated brand science.

The Recoveries in Progress: L'Oreal and Estee Lauder

L'Oreal once again demonstrated why it remains the most consistently reliable compounder in global beauty. The group posted 3.6% reported growth and $13.15 billion in revenues for Q1, making it by far the largest company in our universe. More importantly, comparable (like-for-like) growth reached 7.6%, with its professional products division emerging as a standout contributor. The quarter was also marked by the completion of the Kering Beaute acquisition on March 31, 2026, which brought the Creed fragrance house and long-term beauty licenses for several Kering fashion maisons under the L'Oreal umbrella -- a transaction that meaningfully extends its reach into ultra-premium fragrance. L'Oreal continues to outperform the global beauty market in aggregate, driven by its balanced geographic and category exposure, and its sustained investment in both innovation and digital marketing infrastructure.

Estee Lauder's 4.6% reported revenue growth marks its third consecutive quarter of organic growth recovery, a signal that its "Beauty Reimagined" restructuring plan -- which involves cutting up to 9,000 to 10,000 positions globally and targeting $800 million to $1 billion in annual savings by fiscal 2027 -- is beginning to yield tangible results. China, which had been the primary source of the company's recent struggles, was the only region to deliver meaningful growth in the quarter, up 6% organically. Adjusted margins improved substantially. However, the recovery remains narrow, and the company faces the challenge of restoring momentum to underperforming brands such as Origins and Too Faced while managing potential divestitures. Estee Lauder remains a recovery story rather than a re-acceleration story, but the direction of travel has meaningfully improved.

Amore Pacific continued its steady performance with 5.0% growth in Q1, broadly consistent with recent trends. The Korean conglomerate is benefiting from the enduring global resonance of K-beauty, particularly in skincare, and from its growing presence in APAC markets beyond Korea. Its more modest scale relative to Western majors gives it agility in category and channel adaptation.

The Challenged: Unilever, Beiersdorf, Coty, and Shiseido

The most instructive stories of the quarter may be those of the companies that are declining -- not because the beauty market has abandoned them, but because each is navigating a distinct structural challenge that the current environment is making harder to paper over.

Unilever's 5.4% decline in Q1 -- consistent with its H2 2025 performance -- reflects the difficulty of managing a sprawling portfolio through a period of strategic repositioning. The company has announced the combination of its Foods business with McCormick, sharpening its focus on beauty, wellbeing, and personal care. But restructuring takes time, and in the interim, the group is undergoing portfolio rationalization that has disrupted top-line momentum. Unilever is a company whose long-term direction appears sensible, but whose near-term numbers reflect the friction of transition.

Beiersdorf's 7.7% reported decline in Q1 was flagged clearly in its full-year guidance, and management was explicit that the quarter should not be treated as an indicator of the full year. The Nivea brand declined 7%, impacted by a demanding prior-year comparison, temporary disruptions in key markets, and delayed effects from product innovations. La Prairie, the group's ultra-luxury skincare line, fell 14.9% due to retail disruptions, though management noted that sell-out dynamics -- the rate at which consumers actually buy products off shelves -- remained positive. The derma division (Eucerin and Aquaphor) was the bright spot, growing 8.2%, illustrating the same trend visible at Galderma and Kenvue: science-backed, dermatologist-recommended products continue to gain share within skincare. Beiersdorf's challenge is to accelerate the repositioning of Nivea toward more efficacy-driven face and body care while sustaining La Prairie's positioning in a soft luxury market.

Coty has now recorded seven consecutive quarters of organic revenue decline, with Q1's negative 1.3% representing a slight improvement in pace but no inflection. The company is undergoing significant restructuring, including a strategic review of its mass color cosmetics business and operations in Brazil. Its Gucci fragrance license -- one of its most valuable assets -- faces uncertainty following Kering's shift of beauty licenses to L'Oreal. The relaunching of Marc Jacobs Beauty through a new licensing agreement with Coty offers a potential growth lever, but Coty's structural challenges across its consumer beauty division remain formidable.

Shiseido reported a modest 1.6% improvement in Q1 relative to recent performance, though the company remains under pressure across most geographies except the Americas, where it grew 5%. Its restructuring initiatives have significantly improved profitability, and management is executing with discipline on cost reduction. The recovery of its Drunk Elephant skincare brand is being closely watched as a potential catalyst for a broader turnaround. Shiseido, like Estee Lauder, is being managed as a recovery, with a focus on rebuilding profitability before re-investing in growth.

Mid-Tier and Specialists: Puig, Interparfums, and PROYA

Puig's 0.8% reported growth represents a meaningful deceleration from the mid-single-digit growth it delivered in H1 and H2 of 2025. However, the underlying picture is more constructive. On a like-for-like basis, the company grew 4.7%, with particular strength in APAC and in makeup, which advanced 9.2%. The slowdown in reported terms is a currency and phasing story more than a demand story. Puig's portfolio of prestige fragrance and fashion brands remains well-positioned, and the company is one to watch in the context of potential M&A activity, with market commentary noting ongoing discussions regarding a possible combination with Estee Lauder.

Interparfums posted 1.8% growth, modest but positive for a company that operates in the prestige fragrance segment without the scale advantages of its larger peers. Fragrance remains one of the more resilient beauty categories globally, with both niche and affordable-luxury segments performing well.

PROYA, the Chinese skincare group, returned to near-flat growth at 0.5% after a difficult H2 2025, when revenues fell 10%. The company is closely tied to the health of China's domestic beauty market and the competitive dynamics of the Douyin and Tmall ecommerce channels, where domestic brands have been gaining ground against international incumbents. Its stabilization in Q1 is a constructive signal.

The Structural Forces Reshaping the Industry

Beyond the company-specific dynamics, several macro and structural forces are visibly shaping the industry's trajectory.

The medicalization of beauty is the most powerful secular tailwind in the sector. Galderma's near-breakout growth is perhaps its most visible manifestation, but the trend pervades almost every company in coverage. Consumers are demanding clinical validation, whether through dermatologist endorsement, ingredient transparency, or proximity to pharmaceutical-grade therapeutic products. The boundary between cosmetics and dermatology is dissolving, and the companies best positioned to straddle it -- Galderma, Kenvue's Neutrogena, Beiersdorf's Eucerin, L'Oreal's active cosmetics division -- are systematically outperforming their more traditional counterparts.

Value bifurcation is the second defining phenomenon. The middle of the market -- neither accessibly priced nor clearly differentiated -- is where margin and volume pressure is most acute. The US market illustrates this with unusual clarity: according to Circana, prestige retail dollar sales grew 6% year over year to $8.1 billion in Q1 while mass retail sales rose 7% to $18.1 billion -- for the first time in five years, the two tiers are growing at nearly the same rate. The convergence is not a sign of health across the board; it reflects a consumer who is trading across channels with increasing sophistication, gravitating toward products that deliver visible results at accessible price points and away from brands that can no longer justify a premium on heritage alone. Fragrance, facial skincare, hair treatments, and body care are all holding up, anchored by consumers who continue to invest in self-care routines. The pressure is concentrated on brands in the undifferentiated middle. e.l.f.'s reported 35% headline growth is largely a product of the rhode acquisition rather than organic momentum in its core cosmetics brand, which was essentially flat to slightly negative in Q1. That said, rhode itself is a value-bifurcation story: a prestige-accessible skincare brand priced below luxury incumbents but delivering clinical-quality formulations. Whether through the core e.l.f. brand at drugstore price points or through rhode in Sephora, the e.l.f. universe is consistently positioned at the accessible end of any tier it enters -- and that positioning is precisely what the current consumer environment rewards.

The China recalibration continues to weigh on the global prestige segment. China served as the primary growth engine for prestige beauty for the better part of two decades, and its structural shift is among the most consequential forces currently reshaping the industry. After a difficult 2024, the market showed some recovery in 2025, but consumer confidence has not fully normalized. Younger Chinese shoppers in particular are more price-sensitive and more nationally oriented than the generation before them, increasingly favoring domestic brands and clinically validated efficacy over international heritage. The rules of the China market have changed, and international brands that built large businesses on aspirational positioning are finding that those rules will not simply revert. PROYA's stabilization at near-flat growth after a sharp H2 2025 decline is one signal worth watching; Estee Lauder's China region being the only geography to grow meaningfully in Q1 is another, suggesting that for some international players, China is finally bottoming even if it is not yet recovering.

Social commerce acceleration is rewriting the media economics of beauty marketing. TikTok Shop processed over $3.4 billion in beauty-related transactions in Q1 alone, a 41% increase year over year, and beauty captured 20% of total dollar spending on the platform -- making it the dominant category in social commerce by a wide margin. Meanwhile Amazon's paid search environment has grown significantly more expensive, with average daily advertising spend in the beauty vertical rising nearly 8% year over year and cost-per-click reaching $1.39. The combined effect is that the cost of visibility is rising sharply across every major digital channel while returns are compressing. Brands that cannot generate genuine organic engagement -- through community, content, or product virality -- are finding that paid media alone is no longer sufficient to sustain growth. Brand heritage, in this environment, is not a substitute for relevance.

Outlook

The aggregate 2.6% reported growth across the CARRARA universe in Q1 is a step in the right direction, but it conceals a sector in the middle of genuine structural transition. The winners are those with clear clinical or value-driven differentiation. The companies under pressure are those undergoing restructuring, managing portfolio complexity, or fighting for relevance in a market that is becoming less forgiving of ambiguity.

The balance of 2026 will be shaped significantly by how quickly China stabilizes, how the tariff environment evolves, and whether the wave of restructuring underway at Estee Lauder, Coty, Unilever, and Shiseido begins to translate into top-line momentum rather than just cost savings. Tariffs and wars represent the most unpredictable near-term variable: with packaging and formulation inputs widely sourced from China, Taiwan, and South Korea, any sustained escalation in the US-China trade confrontation would add cost pressure across the supply chain at a moment when most companies have limited room to pass price increases to a value-conscious consumer.